High Intratumoral Accumulation of Stealth Liposomal Doxorubicin in Sarcomas: Rationale for Combination with Radiotherapy

Abstract
Sarcomas are radioresistant tumors, the only curative therapy being radical surgical resection. Stealth® liposomal doxorubicin (Caelyx®) is a novel drug formulation that allows prolonged circulation and high intratumoral concentration. This study investigates the concurrent use of radiotherapy with Caelyx® in a cohort of 7 patients with locally advanced or recurrent sarcoma. Radiotherapy was given as a standard fractionation regimen to a total dose of 70 Gy. Caelyx® was given as a 30-min infusion at a dose of 25 mg/m2